| Stereochemistry | MIXED |
| Molecular Formula | C19H29NO2 |
| Molecular Weight | 303.4391 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 3 / 4 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)NCC(O)COC1=C(C=CC=C1)[C@H]2C[C@@H]3CC[C@H]2C3
InChI
InChIKey=NACJSVRGPPMZRS-BWUCMLAFSA-N
InChI=1S/C19H29NO2/c1-13(2)20-11-16(21)12-22-19-6-4-3-5-17(19)18-10-14-7-8-15(18)9-14/h3-6,13-16,18,20-21H,7-12H2,1-2H3/t14-,15+,16?,18+/m1/s1
| Molecular Formula | C19H29NO2 |
| Molecular Weight | 303.4391 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | EPIMERIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 3 / 4 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Bornaprolol is norbornyl derivative. It is the beta-adrenoceptor blocking agent. The prolonged beta-blocking action of bornaprolol was related to a tight irreversible binding to beta-receptors rather than to pharmacokinetic properties of this drug. In vitro, bornaprolol inhibits isoproterenol-induced stimulation of adenylate cyclase in rat heart homogenate. A dose-related inhibition of the rise in heart rate and blood pressure on sub-maximal exercise 2 h after single doses of bornaprolol. Bornaprolol eliminated mainly by metabolism with a bioavailability that decreases inversely with oral dose. Bornaprolol has a more prolonged action and may prove to be of therapeutic value in situations, such as angina and certain arrhythmias, where sustained high degrees of beta-adrenergic receptor blockade are beneficial. Bornaprolol behaved in man as a non-cardioselective drug.
